Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
复制标题
DOI：
10.1158/1078-0432.ccr-19-1164
复制
发表时间：
2020-01-15
影响因子：
11.5
通讯作者：
Curigliano, Giuseppe
中科院分区：
文献类型：
--
作者：
Hui, Rina;Pearson, Alex;Curigliano, Giuseppe
目的：FGFRI基因在14%的HR+/HER 2（-）乳腺癌患者中扩增。lucitanib，VEGER 1-3，FGFRI-3和PDGER α/β的抑制剂的疗效和安全性进行了评估。患者和方法：HR+/HER 2（-）转移性乳腺癌（MSC）的患者接受口服lucitanib在三个中心确认的队列：（i）FGFR 1扩增，（ii）FGFRI非扩增，11 q13扩增，和（中）FGFR 1和11 q13非扩增。关键入选标准包括东部肿瘤协作组体能状态=一线抗癌治疗，但
Purpose: The FGFRI gene is amplified in 14% of patients with HR+/HER2(-) breast cancer. Efficacy and safety of lucitanib, an inhibitor of VEGER 1-3, FGFRI-3, and PDGER alpha/beta, were assessed.Patients and Methods: Patients with HR+/HER2(-) metastatic breast cancer (MSC) received oral lucitanib in three centrally confirmed cohorts: (i) FGFR1 amplified, (ii) FGFRI nonamplified, 11q13 amplified, and (in) FGFR1 and 11q13 nonamplified. Key inclusion criteria included Eastern Cooperative Oncology Group Performance Status = 1 line of anticancer therapy, but